The Food and Drug Administration April 16 revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. 

Based on its ongoing analysis of emerging scientific data, FDA said that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use. 

For more details, see the FDA news release
 

Related News Articles

Headline
The Federal Emergency Management Agency is reminding stakeholders that funding is available under FEMA’s Public Assistance program, including for…
Headline
The Centers for Medicare & Medicaid Services today released an interim final rule requiring long-term care facilities in the Medicare and Medicaid…
Headline
The Food and Drug Administration today announced the expansion of its emergency use authorization for Pfizer’s COVID-19 vaccine to include adolescents ages 12…
Headline
Illinois health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence in…
Blog
The Centers for Medicare & Medicaid Services recently announced that Medicare will not continue to cover audio-only telehealth visits when the COVID-19…
Headline
Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase…